"AI-assisted drug discovery isn't just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it's no mystery as to why many wish to be underweight in the biotech names, given the tremendous beta and how difficult it is to gain an edge when it's virtually impossible to tell which drugs in the pipeline will make it past all the hurdles (clinical trials)."
"Undoubtedly, there's a lot of dread, skepticism, and even fear about what AI could do to jobs as well as the economy at large. Still, if it means more diseases can be cured, the potential rewards of AI may ultimately outweigh the risks. AI drug discovery has to be one of the most impressive potential applications of the technology, especially as we race ahead into the age of agentics."
AI-assisted drug discovery is gaining traction as biotechnology and biopharma firms adopt AI tools. The biotech sector remains high-risk due to costly, labor-intensive clinical testing and unpredictable pipelines. AI could deliver major value in health and biotech by accelerating discovery and addressing complex biological problems. Successes like DeepMind's AlphaFold provide cause for cautious optimism while biological challenges sustain investor skepticism. AI models are improving, becoming cheaper and easier to adopt, increasing the odds of practical breakthroughs. Specific companies such as Recursion Pharmaceuticals and Eli Lilly are cited as notable AI-focused players to watch.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]